Tuberculous meningitis in adult patients of a Mexican neurological referral
center: A-six-year retrospective cohort study
Maldonado-Diaz Ellis Daniela, MD, MSc <sup>1,2</sup>
Soto-Hernández José Luis, MD <sup>1,</sup>
Salinas-Lara Citlaltepetl, MD, PhD <sup>2</sup>
Kammar-Garcia Ashuin, PhD <sup>3,4</sup>
Cárdenas Graciela, MD, PhD <sup>1</sup>
1 Neuroinfectology Department. Instituto Nacional de Neurología "Manuel Velasco
Suarez". México.
2 Neuropathology Department. Instituto Nacional de Neurología "Manuel Velasco
Suarez". México.
3 Departamento de Atención Institucional Continua y Urgencias. Instituto Nacional de
Ciencias Médicas y Nutrición Salvador Zubirán.
4 Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina.
Instituto Politécnico Nacional.
*Corresponding author: Graciela Cárdenas. Address: Av. Insurgentes Sur 3877, La
Fama, Tlalpan, 14269 Ciudad de México, CDMX Tel: 5556063822, e-mail:
(gcardenas@innn.edu.mx; gracielacardenas@yahoo.com.mx).

#### 24 Abstract

Introduction: Tuberculosis (TB) remains as an important concern of public health
 worldwide because the high prevalence and severe sequelae. Tuberculous meningitis
 (TBM) is the most lethal and disabling form.

Aim: To describe the clinical, laboratory, and neuroimaging characteristics of TBM on admission at neurological center in Mexico City.

30 Methods: Retrospective cohort study at the third level neurological center from 2010 to

2016. Clinical follow-up was evaluated at hospital discharge, three months, and one year either due to lack of follow-up or mortality, during the follow-up the adverse events

33 were registered.

34 Results: One-hundred and six patients were included, 74 (69.8%) males and 32 35 (30.2%) females. From these 31 (29.2%) were HIV-positive. The median age was 35.5 36 (IQR:28-51). Pulmonary TB was found in 25% of the population. Alcoholism was 37 observed in a half of the patients while diabetes in 15%, the latter being significant 38 (p=0.04). Abnormalities in neuroimaging were significant among our population (p=0.003). Only one-third of the population had a positive Lowenstein-Jensen culture. 39 40 There were no differences in clinical outcomes between HIV positive and non-HIV 41 patients.

42 **Conclusion:** Our study shows data to those described in the literature. The initiation of 43 empirical treatment in all patients with a high clinical suspicion of tuberculosis 44 mandatory to try to avoid severe neurological sequels.

45

46 Key words: *Mycobacterium tuberculosis*, tuberculous meningitis, HIV, AIDS.

## 47 Introduction

Tuberculous meningitis (TBM) is the most frequent form of central nervous system (CNS) tuberculosis (1). It represents 1% per year of all tuberculosis (TB) cases, highly disabling and even lethal (1,2).

Globally, TB remains, a chief health problem with an estimated 10.0 million cases and 1.2 million deaths resulting from disease during 2018 (WHO report, 2019), but the global TB burden remains unclear because of underreporting and underdiagnosing. (3). TB is endemic in Mexico, which has the third-highest prevalence in Latin America, just

below Brazil and Peru. During 2019, there were 45,637 cases of pulmonary TB and 396 cases of TBM (4). Many factors are related particularly the high prevalence of risk population as diabetes (DM), HIV/AIDS, and poverty. HIV infection represents the highest risk for latent infection and the progress of clinical TB (5). Other immunocompromised states like chronic steroid use and chronic alcoholism carry the same risk for developing TBM (6,7).

This manuscript aims to describe the clinical, laboratory, and neuroimaging
 characteristics of TBM patients admitted at neurological center in Mexico City.

63

#### 64 Material y methods

#### 65 Study design and patient selection.

Retrospective cohort study carried out in a third level neurological center (Instituto
Nacional de Neurología y Neurocirugía "Manuel Velasco Suarez"). The diagnosis was
based on Marais Consensus of TBM (8). Only patients with definitive and probable TBM
diagnosis were included.

The Modified British Medical Research Council criteria was used to define TBM severity (9), and the comorbidity was defined by Charlson Comorbidity Index (CCI) (10). Besides, a nutritional assessment was performed by the body mass index (BMI) in six categories, as follows  $\leq$ 18.5 malnourishment, 18.5-24.9 average weight, overweight  $\geq$ 25, and obesity  $\geq$  30 (11). Strictly neurological examinations were performed to state sequels.

Clinical follow-up was evaluated at hospital discharge, three-months, and one-year after
 hospitalization, either due to lack of follow-up or mortality. All adverse events were
 register during the clinical follow-up.

This study protocol was approved (protocol 85/17) by the research and ethics committees of the Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez".

82

#### 83 Statistical analysis.

All qualitative variables were expressed in frequencies and percentages. The data were compared between HIV-positive and Non-HIV patients; the categorical comparison was made using the  $\chi^2$  or Fisher's exact test. Quantitative variables were expressed as median and rage. A Mann-Whitney test based on data behavior in the Kolmogorov-Smirnov test was used for comparison between groups. Differences were considered, statistically significant at p<0.05. Data were analyzed using SPSS v.21 (IBM Inc., Armonk, NY).

91

#### 92 **Results**

### 93 Epidemiological data

From January 2010 to December 2016, One-hundred and six patients and the clinical, laboratory and neuroimaging characteristics were collected from medical records. For statistical analysis, two groups were considered: HIV-positive 31 (29 %) and non-HIV infected 75 (71%). In the first group, the median viral load was 146657 copies (IQR: 73006.5-555664.8), median T CD4 lymphocyte cell count of 10 (IQR: 3.3-16.5), and median T CD8 lymphocyte cell count of 63 (IQR 52-78). Male population predominated 74 (70 %) (p=0.003).

101

### 102 Clinical and neuroimaging characteristics

The median of age was 35.5 (IQR:28-51), higher in non-HIV infected. The weight and body mass index was similar between the HIV infected and non-infected patients. Several risk factors were observed, alcoholism in 55 (52 %), diabetes mellitus in 16 (15%); interestingly, previous pulmonary TB was observed in 24 (25%). Only diabetes was statistically different between groups, predominated in non- HIV patients (p=0.04) (Table 1).

109 Clinical symptoms included systemic one (weight loss 38% and fever 50%), 110 neurological symptoms (dizziness, lethargy, or altered consciousness) observed in 80 111 patients (76%), include seizures in 70 (66%) and meningeal sign in 49 (46%). No 112 statistical differences were observed between groups (Table 2).

According to the British Medical Research Council, stage I, was observed in 51 patients (48%), grade II in 38 patients (36%), and finally, grade III in 17 patients (16%); no statistical differences were observed between HIV-positive and non-HIV infected.

116 Charlson's Comorbidity Index was also evaluated. Low risk was observed in 9% (9) 117 and high risk in 37% (39) as high risk. In this latter, a significantly higher proportion of 118 patients were HIV-positive (p=0.0001).

119

## 120 CSF cytochemical and laboratory findings

All patients showed inflammatory profiles in the cytochemical analysis of CSF. Median glycorrhachia was 47 mg/dL (ranges 18-64), proteinorachia 95 mg/dL (44-188) and cellularity 53.5 cells/mm<sup>3</sup> (6-195). Th median CSF adenosine deaminase level was 7 UI/L (3-14). No differences were observed between groups. Median leukocytes were 8.300 mm<sup>3</sup> (5.9-10.7). Non-HIV infected showed leukocytosis (p=0.001). Only one-third of the patients had any Lowenstein-Jensen cultures (Table 3).

Neuroimaging was performed in 79 (75%) of patients during hospitalization: Main abnormalities which predominated in non-HIV infected were vasculitis (p=0.03), parenchymal granulomas (p=0.02) and basal enhancement (p=0.06), no differences between groups were observed in hydrocephalus (Table 4). Transcranial doppler showed vasculitis in 37.7% of patients.

132

### 133 **Treatment**

All patients received antituberculous (DOTBAL) treatment a combination of Ethambutol, Pyrazinamide, Isoniazid, and rifampicin (Intensive phase) for two months and Isoniazid and rifampicin (Support phase) for 12 to 15 months. During hospitalization, patients also received intravenous dexamethasone at 0.3mg/kg/day for two weeks and later, switched on oral prednisone with gradually tapered. Antiretroviral therapy (ART) was

started in the population with HIV-positive; median viral load at six months after treatment was 131 (IQR: 40-278), CD4 cell count 170 (IQR: 149-279), and CD8 cell count 55.5 (IQR: 43.5-62.3). There were no significant differences between survivors and those who died during the study.

143

## 144 Neurological sequels and clinical outcomes

Surviving patients were 86 (81%), and 49 (57%) developed neurological sequels, particularly motor deficits in 23%, cranial neuropathy in 20% and cognitive complaints in 147 14%. The whole mortality rate was 19%, without differences between groups. In HIVpositive patient, mortality was more frequently (19.4% vs. 18.7%) observed during hospitalization while non-HIV infected, 85% died within the first year of clinical follow-up.

150

### 151 Discussion

152 Meningeal tuberculosis is one of the most difficult causes of meningitis to diagnose due 153 to the difficulties in identifying mycobacteria, which is why any patient with any 154 symptoms and signs of meningitis should be considered TB infected in regions with a 155 high prevalence or in population of high risk. It is important to state that Mexico has the 156 third place of TB prevalence after Brazil and Peru (WHO 2019), TBM is an infectious 157 disease with high rates of disability and mortality (12), worldwide the prevalence of 158 disseminated disease vary between 30-50% of infected patients (WHO 2019) while in 159 the current report, our series showed 25% of active lung TB.

According to TB risk factors, HIV and diabetes are the main described in the literature (13) but others such as drugs abuse, and alcoholism are important. In a Mexican cohort

study in Tijuana, Baja California includes 41 TB patients, in which 51% were drug users,
and 27% of alcoholics (14). This data contrasted with our series where only 10% were
drug users while 52% alcoholics.

165 Clinical presentation of TBM is highly pleomorphic but includes cranial nerve palsy, 166 headache, meningeal syndrome, and mental alterations. A study carried out in Brazil in 167 2013, in which 300 patients were included, reported upon admission alterations in the 168 state of consciousness in 61% (15) while in our series 16% of population had coma, this 169 data may indicate a delay in the diagnosis due to delays in consultation.

Delays in the diagnosis seem to be a common problem in low-income countries, in fact in a Peruvian study of 3802 patients, the clinical severity according to British Medical Research in most than a half of population was stage II (16), another example is the prospective cohort conducted by Siddiqi Omar in Zambia (Siddiqi OK et al. 2019) with 500 TB patients were almost a half (46%) presented stage II. In comparison in our series, 48% presented stage I.

176 Neuroimaging is an important diagnostic tool, particularly in CNS TB where 177 bacteriological or molecular diagnosis (geneXpert) is less sensitive (17). It is frequent to 178 found neuroimaging abnormalities in patients with severe disease (18). In our institution, 179 the first performed approach was CT-scan, where specific findings as vasculitis, 180 hydrocephalus and granulomas are highly suspicious of TBM. CT- scan abnormalities 181 were, frequent in non-HIV infected. In our series, it was observed on Transcranial 182 doppler an increased flow velocity in the middle cerebral artery (MCA) in 38%, this data 183 contrast with a report in a TBM pediatric population where up to 70% of the population 184 presented vasculitis (19). In a Malaysian study, in a cohort of 51 patients it was

observed cerebral infarcts in 67% (the most frequently affected areas were basal
ganglia) as well as secondary vasculitis in MCA in 25% of population (20).

The global mortality reported in our series was 19%, which is comparable with another Mexican study data conducted by García- Grimshaw M. Et al. In this series a cohort of 41 adult patients was reported. The median age was 28-years old and mortality of 190 19.5% (14).

TBM has been reported to enhance HIV replication in alveolar macrophages and peripheral blood T cells through cytokine and antigen-mediated cell activation. In a study carried out in South Africa (21), 105 patients were included, all HIV-positive without antiretroviral therapy, reported a T CD4 lymphocytes count upon admission of 78 (IQR: 45-286) while after the initiation of ARV treatment the T CD4 lymphocytes count was 130 (IQR: 76-336) with no statistically significant difference, our population had a similar behavior.

In a Vietnam cohort study of 1699 TBM patients, it was reported that 951 were non-HIV infected and were 748 HIV-positive, in this cohort the mortality at 9-months was 35%, and the more common predictors for increased mortality were the higher stage of Medical Research Council and the lower CSF lymphocyte cell count (22).

The relationships among initial disease severity, long-term structural changes, and altered cognitive function in patients with TBM have not been fully studied, Chen Hsiu-Ling et al, in 2015 (23) corroborate that initial disease's severity correlated to long-term structural abnormalities and cognitive function impairments. Individual disease severity assessed in acute illness is related to a long-term structural deficit, especially in the right caudate nucleus. These findings underscore the importance of evaluating initial

disease severity to predict long-term disease outcomes. In our series only 37 (34.9%)
had a cognitive evaluation.

An important fact to highlight is that the PanAmerican Health Organization reported in 2018 that the tuberculosis rate incidence in South America was 46.2 per 100,000 2018 people, while in Mexico 25.9 per 100,000 respectively (24). Comorbidities are a 2018 challenge in our country, where 30-40% of tuberculosis of patients has diabetes; in our 2019 series only 15% reported this comorbidity.

The limitations of our study include the small sample of patients, the lack of availability of molecular diagnostic tools and the retrospective nature of the study itself. Despite of

this our data shows important findings in a population of a referral neurological center.

218

#### 219 Conclusion

The clinical, laboratory, and neuroimaging characteristics between the population with HIV- positive and non-HIV infected shows no marked differences, particularly the presence of hydrocephalus. It is mandatory to start empirical treatment in all patients with a strong suspicion of TBM despite no mycobacterial isolation on CSF cultures or negative molecular diagnostic.

225

## 226 **Declarations of interest:** none

227

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

230

#### 231 References

- Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, et al.
   Tuberculous meningitis. Nat Rev Neurol. 2017;13:581–598.
- Zunt JR. Tuberculosis of the Central Nervous System. Continuum (Minneap Minn). 2018;24(5):1422-1438.
- 237 3. Chin JH. Tuberculous meningitis: a neglected tropical disease? Neurol Clin
   238 Pract. 2019;9;152–154.
- 4. Secretaría de Salud. Centro Nacional de Programas Preventivos y Control de
   Enfermedades (CENAPRECE). Cifras oficiales de tuberculosis. Available
   from:www.cenaprece.salud.gob.mx/programas/interior/micobacteriosis (acessed
   April 2020)
- 5. Bello-López JM, León-García G, Rojas-Bernabé A, Fernández-Sánchez V,
   García-Hernández O, Mancilla-Rámirez J, et al. Morbidity trends and risk of
   tuberculosis: Mexico 2007–2017. Can Respir J. 2019;2019:1–9.
- 246
   6. Davis A, Meintjes G, Wilkinson RJ. Treatment of Tuberculous Meningitis and Its
   247
   Complications in Adults. Curr Treat Options Neurol. 2018;20(3):5
- Chin JH. Tuberculous meningitis: Diagnostic and therapeutic challenges. Neurol
   Clin Pract. 2014;4(3):199-205
- 8. Marais S, Thwaites G, Schoeman JF, Török ME, Misra UK, Prasad K, et al.
  Tuberculous meningitis: a uniform case definition for use in clinical research.
- Lancet Infect Dis. 2010;10(11):803-812.

- 9. Medical Research Council. Streptomycin treatment of tuberculous meningitis.
  Lancet. 1948;1:497-500
- 255 10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
- 256 prognostic comorbidity in longitudinal studies: development and validation. J
- 257 Chronic Dis. 1987;40(5):373-383
- 11. World Health Organization. Global Tuberculosis Report. Available from:
   https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-
- eng.pdf?ua=1(accessed April 04, 2020).
- 12. Luo M, Wang W, Zeng Q, Luo Y, Yang X. Tuberculous meningitis diagnosis and
   treatment in adults: A series of 189 suspected cases. Experimental and
   therapeutic medicine. 2018;16(3):2770–2776.
- 264 13. Guerrero de Leon JE, Rodriguez Leyva L. Tuberculosis in the Central Nervous
   265 System. Acta Scientific Microbiology. 2020;3(3):1-7
- 266 14. García-Grimshaw M, Gutiérrez-Manjarrez F A, Navarro-Álvarez S, González-
- Duarte A. Clinical, Imaging, and Laboratory Characteristics of Adult Mexican
   Patients with Tuberculous Meningitis: A Retrospective Cohort Study. J Epidemiol
   Glob Health. 2020;10(1):59–64.
- 15. Anselmo L, Feliciano C, Mauad F, do Nascimento M P, Pocente R C, Silva J M,
  et al. A predictive score followed by nucleic acid amplification for adult
  tuberculous meningitis diagnosis in Southern Brazil. J Neurol Sci. 2017;379:
  253–258.

- 16. Soria J, Metcalf T, Mori N, Newby R E, Montano S M, Huaroto L, et al. Mortality
  in hospitalized patients with tuberculous meningitis. BMC infectious diseases.
  2019:19(1):9.
- 17. Metcalf T, Soria J, Silvia MM, Ticona E, Carlton AE, Huaroto L, et al. Evaluation
- of the GeneXpert MTB/RIF in patients with presumptive tuberculous mneingitis.
- 279 PLoS ONE 13(6):e0198695
- 18. Taheri S, Karimi M, Haghighatkhah MA, Pourghorban H, Samadian RM, Delavar Kasmaei H. Central nervous system tuberculosis: an imaging-focused review of a
   reemerging disease. Radiol Res Pract. 2015;202806.
- 19. van Toorn R, Schaaf HS, Solomons R, Laubscher JA, Schoeman JF. The value
   of transcranial Doppler imaging in children with tuberculous meningitis. Childs
   NervSyst. 2014;30(10):1711–1716.
- 286 20. Tai M S, Sharma V K. Role of Transcranial Doppler in the Evaluation of
   287 Vasculopathy in Tuberculous Meningitis. PloS one. 2016;11(10):1-11.
- 288 21. Seipone ID, Singh R, Patel V B, Singh A, Gordon ML, Muema DM, et al.
  289 Tuberculous meningitis is associated with higher cerebrospinal HIV-1 viral loads
  290 compared to other HIV-1-associated meningitides. PloS one.
  291 2018;13(2):e0192060.
- 292 22. Thao LTP, Heemskerk AD, Geskus RB, Mai NTH, Ha DTM, Chau TTH, et al.
   293 Prognostic models for 9-month mortality in tuberculous meningitis. Clin Infect Dis
   294 2018;66(4):523–532.

295	23. Chen HL, Lu CH, Chang CD, Chen PC, Chen MH, Hsu NW, et al. Structural
296	deficits and cognitive impairment in tuberculous meningitis. BMC Infect Dis.
297	2015;15(279):3-9.
298	24. Pan American Health Organization. Tuberculosis in the Americas 2018. Pan
299	American Health Organization; Washington, DC, USA: 2018. (accessed on
300	August 2018). Available online: www.paho.org
301	
302	
303	
304	
305	
306	
307	
308	
309	
310	
311	
312	
313	
314	
315	
316	
317	

# **Table 1.** Demographic characteristics of patients

	Total n=106	HIV infected n=31	Non-HIV infected n=75	p value
Sex, n (%)				
Woman	32 (30.2)	3 (9.7)	29 (38.7)	0.003
Men	74 (69.8)	28 (90.3)	46 (61.3)	-
Weight, Kg	70 (60-77.4)	70 (62.9-79)	70 (59-77)	0.4
Body mass index	25 (23.4-28)	24.5 (21.7- 27.8)	25 (23.5- 28.1)	0.4
Age, years	35.5 (28-51)	32 (29-35)	42 (28-55)	0.01
Age groups, n (%)				
≤20	9 (8.5)	1 (3.2)	8 (10.7)	0.02
21-30	27 (25.5)	11 (35.5)	16 (21.3)	
31-40	26 (24.5)	13 (41.9)	13 (17.3)	
41-50	15 (14.2)	4 (12.9)	11 (14.7)	
50-59	16 (15.1)	2 (6.5)	14 (18.7)	-
>60	13 (12.3)	0 (0)	13 (17.3)	
Risk factors, n (%)				
Previously lung TB	24 (25)	8 (28.6)	16 (23.5)	0.6
DM	16 (15.1)	1 (3.2)	15 (20)	0.04
Malnourishment	13 (12.6)	4 (12.9)	9 (12.5)	0.9
Alcoholism	55 (51.9.)	20 (64.5)	35 (46.7)	0.09
Cocain	3 (2.8)	2 (6.5)	1 (1.3)	0.9
Marihuana	7 (6.6)	4 (12.9)	3 (4)	0.9
Methamphetamines	1 (0.9)	1 (3.2)	0 (0)	0.9

# 326 **Table 2.** Clinical characteristics of population

	Total n=106	HIV infected n=31	Non-HIV infected n=75	p value	
Weight loss, n (%)	40 (37.7)	14 (45.2)	26 (34.7)	0.4	
Fever, n (%)	52 (49.5)	15 (50)	37 (49.3)	0.9	
Combe test, n (%)	20 (18.9)	6 (19.4)	14 (18.7)	0.9	
Meningean signs, n (%)	49 (46.2)	12 (38.7)	37 (49.3)	0.3	
Seizures, n (%)	70 (66)	21 (67.7)	49 (65.3)	0.8	
Neurological symptoms, n (%)	80 (75.5)	24 (77.4)	56 (74.6)	0.6	
GCS	15 (15-15)	15 (15-15)	15 (15-15)	0.3	
Severity, n (%)					
BRMC I	51 (48.1)	9 (29)	42 (56)	0.09	
BRMC II	38 (35.8)	17 (54.8)	21 (28)		
BRMC III	17 (16)	5 (16.1)	12 (16)		
CCI	1 (0-6)	6 (6-7)	2 (1-3)	<0.0001	
Comorbidity, n (%)					
Absent	58 (54.7)	2 (6.5)	56 (74.7)	<0.0001	
Low	9 (8.5)	1 (3.2)	8 (10.7)		
Hight	39 (36.8)	28 (90.3)	11 (14.7)		
Nutritional status, n (%)	106	31	75		
Malnourishment	4 (3.8)	2 (6.5)	2 (2.6)	0.4	
Normal weight	49 (46.2)	17 (54.8)	32 (42.7)		
Overweight	39 (36.9)	11 (35.5)	28 (37.3)		
Obesity I	10 (9.4)	1 (3.2)	9 (12)		
Obesity II	3 (2.8)	2 (6.5)	1 (1.3)		
Obesity III	1 (0.9)	0 (0)	1 (1.3)		

GCS: Glasgow coma scale, CCI: Charlson comorbility index

327

# **Table 3.** Ancillary test performed in patients

Sodium, mmol/L       136 (133-139)       136 (134-141)       136 (133-139)       0.5         Glucose, mg/dL       106 (89- 125.5)       96 (88-113)       109 (91- 180.5)       0.1         CSF       Image: Comparison of the temporal stress of tempor		Total n=106	HIV positive n=31	Non-HIV n=75	p value
Sodium, mmol/L       136 (133-139)       136 (134-141)       136 (133-139)       0.5         Glucose, mg/dL       106 (89- 125.5)       96 (88-113)       109 (91- 180.5)       0.1         CSF               Glucose, mg/dL       47 (18.3-63.8)       44 (34.5-61.5)       48 (16.8-65.3)       0.7         Proteins, mg/dL       95 (44-188)       98 (44.5-200)       92 (43-186.5)       0.9         Cells       53.5 (6-195)       49.5 (7-141)       63 (5.8-213)       0.7         Lymphocytes       90 (66.3-97)       90.5 (66-96.5)       87 (66.3-97.8)       0.8         Neutrophils       14 (4.5-38.5)       10 (5-83)       15.5 (3.8- 35.8)       0.5         Adenosine deaminase, Ul/L       7 (3-14)       7 (3.8-13)       6 (1.5-15)       0.7         Microbiological test           0.7         Mtb positive       33 (31.1)       10 (32.3)       23 (30.7)       0.9         Data are presented as median (IQR) Data were compared by Man-Whitney U test.	Serum				
Glucose, mg/dL       106 (89- 125.5)       96 (88-113)       109 (91- 180.5)       0.1         CSF       Image: Constraint of the state o	Leukocytes, x10 <sup>9</sup> /L	8.3 (5.9-10.7)	6.8 (5.4-8.9)	8.9 (6.7-11.8)	0.001
125.5)       180.5)         CSF       Image: constraint of the state of t	Sodium, mmol/L	136 (133-139)	136 (134-141)	136 (133-139)	0.5
Glucose, mg/dL47 (18.3-63.8)44 (34.5-61.5)48 (16.8-65.3)0.7Proteins, mg/dL95 (44-188)98 (44.5-200)92 (43-186.5)0.9Cells53.5 (6-195)49.5 (7-141)63 (5.8-213)0.7Lymphocytes90 (66.3-97)90.5 (66-96.5)87 (66.3-97.8)0.8Neutrophils14 (4.5-38.5)10 (5-83)15.5 (3.8- 35.8)0.5Adenosine deaminase, UI/L7 (3-14)7 (3.8-13)6 (1.5-15)0.7Microbiological test33 (31.1)10 (32.3)23 (30.7)0.9Data are presented as median (IQR) Data were compared by Man-Whitney U test.	Glucose, mg/dL		96 (88-113)	· ·	0.1
Proteins, mg/dL         95 (44-188)         98 (44.5-200)         92 (43-186.5)         0.9           Cells         53.5 (6-195)         49.5 (7-141)         63 (5.8-213)         0.7           Lymphocytes         90 (66.3-97)         90.5 (66-96.5)         87 (66.3-97.8)         0.8           Neutrophils         14 (4.5-38.5)         10 (5-83)         15.5 (3.8- 35.8)         0.5           Adenosine deaminase, UI/L         7 (3-14)         7 (3.8-13)         6 (1.5-15)         0.7           Microbiological test	CSF				
Cells       53.5 (6-195)       49.5 (7-141)       63 (5.8-213)       0.7         Lymphocytes       90 (66.3-97)       90.5 (66-96.5)       87 (66.3-97.8)       0.8         Neutrophils       14 (4.5-38.5)       10 (5-83)       15.5 (3.8- 35.8)       0.5         Adenosine deaminase, UI/L       7 (3-14)       7 (3.8-13)       6 (1.5-15)       0.7         Microbiological test       33 (31.1)       10 (32.3)       23 (30.7)       0.9         Data are presented as median (IQR) Data were compared by Man-Whitney U test.	Glucose, mg/dL	47 (18.3-63.8)	44 (34.5-61.5)	48 (16.8-65.3)	0.7
Lymphocytes         90 (66.3-97)         90.5 (66-96.5)         87 (66.3-97.8)         0.8           Neutrophils         14 (4.5-38.5)         10 (5-83)         15.5 (3.8- 35.8)         0.5           Adenosine deaminase, UI/L         7 (3-14)         7 (3.8-13)         6 (1.5-15)         0.7           Microbiological test	Proteins, mg/dL	95 (44-188)	98 (44.5-200)	92 (43-186.5)	0.9
Neutrophils         14 (4.5-38.5)         10 (5-83)         15.5 (3.8- 35.8)         0.5           Adenosine deaminase, UI/L         7 (3-14)         7 (3.8-13)         6 (1.5-15)         0.7           Microbiological test                 Mtb positive         33 (31.1)         10 (32.3)         23 (30.7)         0.9           Data are presented as median (IQR) Data were compared by Man-Whitney U test.	Cells	53.5 (6-195)	49.5 (7-141)	63 (5.8-213)	0.7
Adenosine deaminase, UI/L7 (3-14)7 (3.8-13)6 (1.5-15)0.7Microbiological test </td <td>Lymphocytes</td> <td>90 (66.3-97)</td> <td>90.5 (66-96.5)</td> <td>87 (66.3-97.8)</td> <td>0.8</td>	Lymphocytes	90 (66.3-97)	90.5 (66-96.5)	87 (66.3-97.8)	0.8
deaminase, UI/L(1,1,2,3)Microbiological test10 (32.3)Mtb positive33 (31.1)10 (32.3)23 (30.7)Data are presented as median (IQR) Data were compared by Man-Whitney U test.	Neutrophils	14 (4.5-38.5)	10 (5-83)	· ·	0.5
Mtb positive33 (31.1)10 (32.3)23 (30.7)0.9Data are presented as median (IQR) Data were compared by Man-Whitney U test.		7 (3-14)	7 (3.8-13)	6 (1.5-15)	0.7
Data are presented as median (IQR) Data were compared by Man-Whitney U test.	Vicrobiological test				
	Mtb positive	33 (31.1)	10 (32.3)	23 (30.7)	0.9
CSF: Cerebro spinal fluid, Mtb: Mycobacterium tuberculosis	•	· · ·		•	ey U test.

# 338 **Table 4.** Neuroimaging characteristics

	Total n=106	HIV positive n=31	Non-HIV infected n=75	p value
Vasculitis	37 (34.9)	6 (19.4)	31 (41.3)	0.03
Hydrocephalus	9 (8.5)	1 (3.2)	8 (10.7)	0.2
Meningitis	42 (36.6)	8 (25.8)	34 (45.3)	0.06
Tuberculoma	57 (53.8)	11 (35.4)	46 (61.3)	0.02
Data are presented as	s n (%). Data were o	compared Chi Sq	uare or Fisher	exact tes